Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Translation

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...

Translation

Translation

Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CerS2 Is a Druggable Target in Triple-Negative Breast Cancer.

Molecular cancer therapeutics·2026

Same author

When Coconspirators Avert the Crime: Clonal Hematopoiesis Driven by TET2 Loss Improves Response to Cancer Immunotherapy.

Cancer research·2026

Same author

DNMT3A R882H Is Not Required for Disease Maintenance in Primary Human AML but Is Associated with Increased Leukemia Stem Cell Frequency.

Cancer discovery·2025

Same author

Clonal hematopoiesis driven by Dnmt3a mutations promotes metabolic disease development in mice.

The Journal of clinical investigation·2025

Same author

Metallothionein 1: the Achilles heel of <i>Dnmt3a;Npm1</i>-mutant acute myeloid leukemia.

Haematologica·2025

Same author

CerS2 is a druggable target in triple-negative breast cancer.

bioRxiv : the preprint server for biology·2025

Search research articles

Related Experiment Video

Updated: Dec 4, 2025

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

Alterations to DNMT3A in Hematologic Malignancies.

Kartika Venugopal¹, Yang Feng¹, Daniil Shabashvili¹

¹Department of Pharmacology and Therapeutics, University of Florida (UF) College of Medicine, Gainesville, Florida.

Cancer Research

|October 22, 2020

Summary

Mutations in the DNA methyltransferase DNMT3A are common in blood cancers. This review details how these epigenetic changes drive cancer and impact immunity, informing new therapies.

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

Related Experiment Videos

Last Updated: Dec 4, 2025

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

Area of Science:

Genetics
Epigenetics
Oncology

Background:

Recurrent somatic alterations in epigenetic modifier genes, particularly DNMT3A, are frequent in hematologic malignancies.
DNMT3A mutations are observed in both myeloid and lymphoid cancers, as well as in clonal hematopoiesis.
Understanding DNMT3A's role is crucial for deciphering cancer pathogenesis.

Purpose of the Study:

To review recent advances in understanding DNMT3A mutations in hematologic malignancies.
To explore the biochemical and structural consequences of DNMT3A mutations.
To summarize the impact of mutant DNMT3A on epigenetic patterns, gene expression, clonal hematopoiesis, and immune function.

Main Methods:

Literature review of large-scale genomic studies.
Analysis of biochemical and structural data related to DNMT3A mutations.
Synthesis of findings on epigenetic changes and their role in disease.

Main Results:

DNMT3A mutations alter DNA methylation catalysis and binding interactions.
These alterations lead to changes in epigenetic patterns and gene expression.
Mutant DNMT3A influences clonal hematopoiesis, immune cell function, and inflammatory responses.

Conclusions:

DNMT3A mutations are key drivers in hematologic malignancies and clonal hematopoiesis.
Understanding these mutations provides insights into disease mechanisms and immune dysregulation.
This knowledge is essential for developing targeted therapeutic strategies for DNMT3A-mutated cancers.